Browse drugs

…s associated with 11.9% greater weight reduction (13 RCTs), and tirzepatide was associated with 16.2% greater weight reduction (6 RCTs).51 …

…s introduced, initially referring to TB resistant to isoniazid, rifampicin, and at least three of the six main classes of second line drug…

…ow (see section on Current treatments). The antifibrotic drugs, pirfenidone and nintedanib, are established treatments for idiopathic pulmo…

…CD16+/CD137+) at 1 week after the first infusion, regardless of W0180 dose (online supplemental figure S7).Of the pro-inflammatory cy…

…ducted, no agents have received approval, with the exception of valrubicin, largely attributed to factors such as the varied prior BCG exp…

…particularly relevant for GLP-1 receptor agonists. For example, semaglutide has demonstrated dose-dependent effects on glycemic control and…

…city, with G3/4 events reported in 22% compared with 14% in the nivolumab monotherapy arm. An update presented at the European Society of…

…), atezolizumab (Tecentriq), osimertinib (Tagrisso), ceritinib (Zykadia) and nintedanib (Vargatef). EMA labels for all products include…

…intensification or change was 1.6 (0.7) and 1.4 (0.7) years for semaglutide and alternative treatment, with no subgroup differences noted (…

…TEZO, atezolizumab; BINI, binimetinib; COBI, cobimetinib; ENCO, encorafenib; ESS, effective sample size; DAB, dabrafenib; NIVO, nivolumab; …

…nsporter 2 inhibitors, and insulin, as well as length of use of metformin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase 4 inhi…

…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …